Globalance World

Loading…

The Health score of this Portfolio is 40

Health

The Globalance Footprint® shows you the impacts of your assets around the world - individually and at a glance. Our framework is simple and objective. Using nine themes, we assess your contribution to sustainable foundations for economic prosperity, the future viability of society and the preservation of our natural resources.

40

Health

57%

of this invested capital features an adverse footprint in Health.

29%

of this invested capital features a balanced footprint in Health.

14%

of this invested capital features a positive footprint in Health.

What's at stake

A smoothly functioning healthcare system is a fundamental building block for a sustainable society. Through the world, healthcare schemes are under pressure, either because they can’t assure proper medical care or because the related costs are exploding. The «access to medicine» debate focuses on broadening the range of treatments even for rare diseases. For its part, the food industry is being called upon to provide healthy nourishment and promote wellbeing.

Health Scores of your Assets

40

Portfolio Footprint Score

0100

Data source: Globalance

 
Asset Name
Health
Society
Total Footprint
% of portfolio
ABIOMED, Inc.9090790.0%
Agilent Technologies, Inc.8686830.1%
Target Corporation8686640.3%
Assurant, Inc.8484720.0%
Mettler-Toledo International Inc.8484830.1%

Why does it matter

Global Challenges

  • Undersupply of medicines and healthcare facilities

  • Rising direct costs of the healthcare system

  • Higher indirect costs to the economy

  • The spread of rare diseases

  • Recalls of deficient products

  • Health risks

Global Goals

  • Access to affordable healthcare

  • Diversity of therapies and medical technologies even for “orphan” diseases

  • New business models that incorporate differential pricing

  • Safety and quality of medicines

Relevance for Investors

Access to medicine in the developing world is improving, which results in higher life expectancy. Pharmaceutical companies have a direct influence on the speed of this development through pricing and patent policy. Pharmaceutical companies follow an economic agenda along with ethical considerations, when making medicine available to poor population segments. There is a trade-off between making a product available at low cost (and thus low profit) and purely commercial considerations. Growing demand for pharmaceuticals in many countries (led by Brazil, Russia, India and China) is recognized as a major driver for the industry today. Healthier populations are more productive and contribute to economic growth. Companies which make their products available to low-income population segments will profit from brand recognition and trust as developing economies start to grow and can increasingly afford to pay higher prices.

Latest Insights

Globalance assesses and comments: With our Insights, we show you what the developments in the world mean for your assets. The focus is on future-oriented answers to major challenges.

See more assets or a Globalance Portfolio

Register Now